
Sun Pharmaceuticals Q1 Results FY26: Q1 PAT Rose -19.64% to ₹2,278.63 Crore; Revenue Surged 9.47% YoY
Sun Pharmaceuticals Q1 Results FY26
Updated: 31 Jul 2025 • 6:25 pm
Posted by:

Sun Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | 13,851.4 | 12,652.75 |
| Profit Before Tax (PBT) | 4,766.12 | 4,140.17 |
| Profit After Tax (PAT) | 2,278.63 | 2,835.62 |
(Figures in crores)
Sun Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | 5,601.96 | 4,498.07 |
| Profit Before Tax (PBT) | 1,994.84 | 843.81 |
| Profit After Tax (PAT) | 753.53 | 237.82 |
(Figures in crores)
Sun Pharmaceuticals Results FY26 Highlights (Q1 FY26 vs FY25)
- Sun Pharmaceuticals clocked Q1 FY26 consolidated revenue of ₹13,851.4 crores vs ₹12,652.75 crores.
- On the profit front, Sun Pharmaceuticals earned a consolidated PAT of ₹2,278.63 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹2,835.62 crore.
- Consolidated PAT rose for the first quarter of FY26, was -19.64% YoY, and revenue soared 9.47% YoY.
- As per the standalone figures, the quarterly PAT of Sun Pharmaceuticals has increased by 216.85%, and revenue has surged by 24.54% YoY.
Sun Pharmaceuticals Share Price Performance
On the opening bell of 31st July 2025, the shares of Sun Pharmaceuticals opened at ₹1,715 per share. However, the initial gains are sustained as of now, and Sun Pharmaceuticals shares are trading at ₹1,706.70 per share, lower than their opening price.
Considering the long-term performance, Sun Pharmaceuticals shares have yielded returns of approximately 0.12% over the past year, and 5-year returns stand at 230.58%. Over the maximum timeframe, Sun Pharmaceuticals shares provided investors with 12,622.80% returns. However, one must ignore the risk of volatility in the stock market and invest in Sun Pharmaceuticals shares after thorough research.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your research before investing in shares and other securities.
Also Read : SAIL Q1 Results FY26: Q1 PAT Rose 810.47% to ₹744.58 Crore; Revenue Surged 8.02% YoY
Recent Articles
Flysbs Aviation IPO GMP & Review: Apply or Avoid?
Sri Lotus Developers IPO GMP: Day 1 IPO Live Updates
Varun Beverages Q1 Results FY26: Q1 PAT Surged 5.14% to ₹1,317.02 Crore; Revenue Dropped 2.33% YoY
Takyon Networks IPO GMP: Day 1 IPO Live Updates
Asian Paints Q1 Results FY26: Q1 PAT Plunged 6.00% to ₹1,099.77 Crore; Revenue Dropped 0.35% YoY
Recent Articles

Intraday Stocks for Today: UltraTech Cement, ICICI Bank and HDFC Bank, Analyst Top Picks for 22 July 2026
22 July 2026

Sundaram Long Term Tax Advantage Fund Series IV vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
21 July 2026

Sundaram Long Term Tax Advantage Fund Series III vs UTI Series IV: NAV, Returns and Maturity Status Compared
21 July 2026

Sundaram Long Term Tax Advantage Fund Series II vs SBI Series IV: NAV, Returns and Maturity Status Compared
21 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Intraday Stocks for Today: UltraTech Cement, ICICI Bank and HDFC Bank, Analyst Top Picks for 22 July 2026
Sundaram Long Term Tax Advantage Fund Series IV vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series III vs UTI Series IV: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series II vs SBI Series IV: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series III vs UTI Series VI: NAV, Returns and Maturity Status Compared
Popular this week
Intraday Stocks for Today: UltraTech Cement, ICICI Bank and HDFC Bank, Analyst Top Picks for 22 July 2026
Sundaram Long Term Tax Advantage Fund Series IV vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series III vs UTI Series IV: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series II vs SBI Series IV: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series III vs UTI Series VI: NAV, Returns and Maturity Status Compared

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





